Each Warrant shall be exercisable to acquire one common share of the Company for a period of 24 months from closing of the Offering at an exercise price of $1.75. The Underwriters have now agreed to purchase, on a bought deal basis pursuant to the filing of a prospectus supplement to the Company’s short form base shelf prospectus dated March 12, 2021, an aggregate of 28,000,000 units at a price of $1.25 per Unit for aggregate gross proceeds to the Company of $35 million.Įach Unit consists of one common share and one-half of one common share purchase warrant of the Company. ( CVE:NUMI) ( OTCMKTS:LKYSF) entered into a revised agreement with Eight Capital and Canaccord Genuity (The Underwriters). Numinus Wellness Announces Upsized Bought Deal Public Offering to $35 million Reddit AMA: PharmaTher CEO Fabio Chianelli Conducted An “Ask Me Anything” Q&A Session On r/shroomstocks ♣ģ. Infographic Of The Week: Depression Is The Leading Reason (>2x) Why People In Emotional Distress Self-Treat With Psychedelics Field Trip plans to use the net proceeds to fund the continued advancement of the FT-104 novel psychedelic development program, the establishment of new Field Trip Health centers, and for working capital and general corporate purposes. In connection with the Offering, Field Trip issued 14,661,499 common shares, at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million.įield Trip had pro forma cash and cash equivalents on hand of $113.7 million upon the closure of the Offering. Field Trip Health Closes $95 Million Bought Deal Financing-The Largest In History For A Canadian Psychedelics Companyįield Trip Health ( CNSX:FTRP) ( OTCMKTS:FTRPF) closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021-including the full exercise of the underwriters’ over-allotment option. The study is titled “A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression.” The clinical trial begins enrolling individuals in March 2021.Ĥ. The Phase 2 study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression, a mental health condition that affects approximately 30% of people suffering from major depressive disorder. Novamind’s research, clinics, and psychedelic medicine are changing the way we treat people with #depression, #anxiety, #PTSD, and more. Shroomstocks are about to see a boom in public companies.We’re proud to work with Merck on a clinical trial of a new drug for treatment-resistant depression. Weed has nothing to do with psychedelics, and I trust them less than anybody else in the sector.īut I'll swing trade their companies. They couldn't deliver in the weed sector, yet think their clout affords them some ability to steer an industry focused on psychedelics? What these guys all have in common is that they, pardon my french, shit the bed. Terry Booth from Aurora on the board of PsychMed. Then he started Cannabis Wheaton, which was rebuilt as Auxly.Ī bunch of Aurora guys running Field Trip. He was fired from Tweed because his constant inability to achieve milestones was killing the company. Rifici with Novamed after being fired by Canopy (then Tweed), and then suing politicians when they questioned Canopy's share surge in 2017 (of which he was a majority shareholder). Linton randomly on the board of MindMed after being fired by Constellation Brands. It seems like there is a new company going public every week, and they're helmed by these guys who cut and run from cannabis. There are entirely too many ex-cannabis c-suite guys entering this space after completely mismanaging their LPs. Rifici, the self appointed "godfather of Canadian weed".
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |